Federal cannabis policy moved from theory to action this spring, and three ETFs sit closest to the trade. The AdvisorShares Pure US Cannabis ETF (NYSEARCA:MSOS), the Amplify Seymour Cannabis ETF (NYSEARCA:CNBS), and the AdvisorShares Pure Cannabis ETF (NYSEARCA:YOLO) each offer a different angle on the same catalyst: the Department of Justice’s April 23, 2026 final order rescheduling FDA-approved marijuana products and qualifying state-licensed medical programs from Schedule I to Schedule III.
The order reshapes the industry’s economics while leaving recreational use exactly where it is. State medical operators can now apply for DEA registration through a portal that opened on April 29, and a broader DEA rescheduling hearing is set to begin on June 29. The ETFs below offer investors several ways to play the same theme.
Why Rescheduling Changes the Math
Section 280E is the rule that has been kneecapping cannabis companies for years. It prevents them from deducting normal business expenses, which is why reported earnings look so battered across all US multi‑state operators. Moving cannabis to Schedule III would lift that 280E burden and, just as importantly, clear a path for institutional investors who have mostly stayed away from plant‑touching names because of federal illegality.
Prediction markets are pricing the next leg cautiously. The Polymarket contract on broader rescheduling by year-end shows a 35% implied probability, while a tighter June 30 deadline trades at just 4%. Traders see the path forward but expect it to take time and survive ongoing litigation risk.
MSOS: The Cleanest US Multi-State Operator Bet
MSOS is the clearest single‑ticker way to lean into a US rescheduling story. AdvisorShares runs it as an active fund, and it uses total return swaps to mirror the performance of US plant‑touching multi‑state operators that still can’t list on major exchanges because they remain under Schedule I. If 280E disappears, those swaps are tied to the very companies whose after‑tax cash flow jumps the most.
The price action around the catalyst has been strong. Shares recently closed near $5, up 31% over the past month and 69% over the past year. The year‑to‑date number looks choppy because the fund sold off earlier in the year before the April policy news hit. Long‑term holders are still deep in the red, though, with the ETF down 88% over five years from its post‑SAFE Banking Act peak in 2021.
The portfolio leans heavily on a small group of large MSOs that dominate legal US cannabis revenue. With roughly $1 billion in assets, MSOS is easily the biggest fund in the space, which helps with tighter spreads and gives traders meaningful options liquidity. The expense ratio sits around 0.78%, which is on the higher side for a thematic ETF but typical for an active, swap‑based structure.
There are tradeoffs. The top positions carry double‑digit weights, so a single operator’s earnings miss can move the whole fund. And because the strategy relies on swaps, investors take on counterparty exposure and a tax profile that doesn’t match a standard 1099 equity ETF.
CNBS: The Active, Diversified Alternative
CNBS is the outlier in this group, and that’s the appeal. Tim Seymour runs it with a mix that spans US MSOs, Canadian licensed producers, and the picks‑and‑shovels names that support the industry, everything from real estate to tech to agricultural inputs. That blend won’t pop as hard as a pure MSO basket on a single US headline, but it also won’t crack as easily if the June 29 hearing delivers something narrower than the bulls are hoping for.
Shares trade near $29, up 25% over the past month and 53% over the past year. The expense ratio sits at 0.76%, roughly in line with MSOS, but the fund’s smaller size keeps it off most institutional radars, even with an active mandate.
Curaleaf has typically been the largest position, joined by ancillary names like WM Technology and Innovative Industrial Properties. The active approach lets the manager shift weight between US and Canadian operators as policy evolves, which is the core argument for choosing CNBS over a passive index. If institutional money starts flowing after rescheduling, the service providers and cannabis‑focused REITs stand to benefit alongside the operators themselves.
The tradeoff is straightforward. Smaller AUM means wider spreads, and the diversification that cushions the downside also limits upside if MSOs sprint ahead of the rest of the value chain.
YOLO: The Global Re-Rating Trade
YOLO is the veteran in this group, launching years before MSOS and carrying a broader mandate from the start. It’s an active mix of plant‑touching companies in both the US and abroad, mostly Canadian licensed producers, plus a handful of ancillary names. The portfolio holds about 17 positions, manages roughly $32 million in assets, and charges an expense ratio of 0.51%, the lowest of the three funds.
Its performance profile differs from that of US‑focused ETFs. YOLO trades near $3, up 15% over the past month and 64% over the past year, but still down 4% year‑to‑date. The international tilt has been a headwind, while US‑specific rescheduling headlines have driven the rally, since Canadian LPs don’t get a direct lift from a DEA move to Schedule III.
The case for YOLO leans on a wider view: that US rescheduling sparks a global re‑rating of cannabis equities as the regulatory ceiling rises and capital returns to the sector. In that scenario, Canadian operators with US optionality move higher alongside MSOs. If the global follow‑through doesn’t materialize, YOLO lags a US‑only basket. Its smaller asset base and concentrated lineup amplify both outcomes.
Choosing Between the Three
The three funds line up with three distinct ways to approach the same catalyst. MSOS is built for investors who want the most direct exposure to US federal cannabis policy and who are comfortable with a swap structure and a concentrated group of MSOs. If the thesis centers on 280E relief and follow‑through on DEA reclassification, this is the clearest expression of that view.
CNBS works for investors who want an active manager to guide exposure across the entire cannabis value chain, rather than focusing solely on operators. The appeal is the mix of ancillary companies and cannabis‑focused REITs, which could benefit if institutional capital returns to the sector.
YOLO is the choice for a broader, global re‑rating thesis. It offers the lowest expense ratio and international diversification, but it also has a smaller asset base and the risk that US‑only catalysts continue to drive price action. If the global follow‑through materializes, YOLO participates. If it does not, it trails a US‑focused basket.
Top Gaining Stocks
Top Losing Stocks